A team devoted to creating medicines for diseases that outsmart single targets

We are an interdisciplinary team with a shared vision: bringing the first multi-RNA combination medicines to patients.

Benjamina Bollag Co-founder / CEO

MEng Chemical Engineering, Imperial College. Built and exited Uncommon Bio — $50M raised from Sam Altman, Lowercarbon Capital and Balderton. Entrepreneur First alumna. Two patents.

Dr. Ruth Faram Co-founder / CSO

MSc/PhD Anatomical Neuropharmacology, Oxford; three Oxford postdocs; Paton Prize in Pharmacology. 20+ years in cell and molecular biology. Built and exited Uncommon Bio. Six patents.

Dr. Paul Ford MD, PhD CMO (fractional)

VP/CMO roles at Novartis, Galapagos, Galecto and PureTech Health. Advanced four IPF candidates from pre-clinical into the clinic.

Dr. Rinat Nigmatullin Principal Investigator, Biomaterials

35 years with polymers, 15 in biological applications. 70 peer-reviewed papers, eight patents.

Dr. Ariane Standing, Lead Cell and Molecular Biologist

Dr. Ariane Standing Lead Cell & Molecular Biologist

PhD Genetics, UCL; BSc Cambridge; three postdocs. 20+ years in cell and molecular biology.

Dr. Ajeesh Chandrasekharan Senior Chemist

PhD Chemistry, Queensland; two postdocs, Pusan National University. 20+ years in polymer and materials chemistry.

Dr. Liam Martin Senior Chemist

BSc, PhD Chemistry, Warwick. 8+ years in polymer and materials chemistry.

Dr. Lucas Carminatti-Pantaleão Senior Molecular Biologist

BSc, MSc, PhD Biomedical Sciences, São Paulo; postdoctoral positions. 15+ years in molecular biology and bioinformatics.

Dr. Rupambika Das Senior Scientist

PhD Tissue Engineering, SUTD; postdocs at the Francis Crick Institute and NUS. 10+ years in biotech.

Join us

We hire ahead of the curve.

There are no open roles right now, but the team grows with every programme milestone. If you're an exceptional chemist, biologist, computational scientist or operator who wants to work on combination medicines, get in touch!

Introduce yourself